ReviewBritish journal of cancer2021
The lingering mysteries of metastatic recurrence in breast cancer.
Review in British journal of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 339 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
339 citing papers in PubMed, 5 syntheses or guidelines pooled it, 601 citations in OpenAlex.
- Facilitators and barriers to mammogram screening uptake among Saudi women: A systematic review.Saudi medical journal · 2025Pooled it
- Global determinants of breast cancer mortality: a comprehensive meta-analysis of clinical, demographic, and lifestyle risk factors.BMC public health · 2025Pooled it
- Comparison of robotic, conventional, and endoscopic nipple-sparing mastectomy with immediate prosthetic breast reconstruction for breast cancer: A systematic review and meta-analysis.Biomolecules & biomedicine · 2025Pooled it
- Diagnostic accuracy of machine learning-based magnetic resonance imaging models in breast cancer classification: a systematic review and meta-analysis.World journal of surgical oncology · 2025Pooled it
- Late-stage diagnosis: The driving force behind high breast cancer mortality in Ethiopia: A systematic review and meta-analysis.PloS one · 2024Pooled it
- TCHL - a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, trastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysis.Acta oncologica (Stockholm, Sweden) · 2025Trial
- A truncated TNS3 isoform expressed in metastatic triple negative breast cancer stabilizes FAK and promotes lung metastasis.Oncogene · 2026Article
- Outcomes After Intratumoral Delivery of Immunotherapy in Breast Cancer.Journal of surgical oncology · 2026Observational
- Prominin 2 promotes the progression of breast cancer by inhibiting ferroptosisJournal of translational internal medicine · 2026Article
- Tumor-educated platelets in cancer diagnostics and prognostics: A critical appraisal and roadmap for clinical translation.International journal of cancer · 2026Review
- Breast cancer genomic subtype-specific copy number alterations in metastases.Scientific reports · 2026Article
- Unlocking the ferroptotic window: Lipidomic rewiring and metabolic addiction in EMT-driven breast cancer resistance.Cell death discovery · 2026Review
- Intrinsic and extrinsic regulators of cancer dormancy and awakening.Journal of the National Cancer Center · 2026Review
- Recurrence in the chemotherapy regimen of bladder carcinoma originates from quiescent epidermoid-like cells.Nature communications · 2026Article
- Endocrine therapy reprogramming of breast cancer facilitates metastatic escape via upregulation of P-Rex1/Rac1 signalling.Nature communications · 2026Article
- Suppression of NGALR impedes TNBC cell survival, proliferation, invasion, and migration through Akt/mTOR and JAK/STAT3 pathway inhibition.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Results of the feasibility study of clinical trials of the new cancer treatment technology Karanahan for patients with advanced breast cancer.Translational cancer research · 2026Article
- Integrative multi-omics analysis identifies PAICS as a key regulator of epithelial-mesenchymal transition in breast cancer metastasis.Discover oncology · 2026Article
- Article
- AKAP2 is required for assembly of cytoskeletal signaling complexes that promote growth and metastasis of triple-negative breast cancer.The Journal of biological chemistry · 2026Article
279 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Despite being the hallmark of cancer that is responsible for the highest number of deaths, very little is known about the biology of metastasis. Metastatic disease typically manifests after a protracted period of undetectable disease following surgery or systemic therapy, owing to relapse or recurrence. In the case of breast cancer, metastatic relapse can occur months to decades after initial diagnosis and treatment. In this review, we provide an overview of the known key factors that influence metastatic recurrence, with the goal of highlighting the critical unanswered questions that still need to be addressed to make a difference in the mortality of breast cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.